Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore, 18-21 December 2015. New data for BI 1482694* (HM61713**) demonstrate a strong anti-tumour activity (confirmed objective response and disease control rates) with a favourable safety profile in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) whose tumours have acquired the most common mechanism of resistance, the T790M mutation, and have stopped responding to treatment with previous 1st- and/or 2nd-generation EGFR targeted therapies. BI 1482694 is a novel, 3rd-generation, EGFR mutant-specific tyrosine kinase inhibitor (TKI).
Dr Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented, “We are looking forward to presenting the exciting new data from our oncology portfolio at ESMO Asia 2015 Congress. The results of the two head-to-head trials of afatinib versus 1st-generation TKIs, gefitinib and erlotinib, could provide guidance to the practicing oncologist on the choice of TKIs in EGFR-mutated and squamous cell lung cancer, respectively. We are also excited to present the latest results for BI 1482694, Boehringer Ingelheim’s newest compound, as we strive to extend the continuum of treatment with targeted therapies for patients with EGFR-mutated lung cancer and delay the burdensome side effects of chemotherapy for even longer.”
Data for Boehringer Ingelheim Oncology Compounds at ESMO Asia 2015 Congress
| Title | Authors | Abstract Details | |||
| BI 1482694* | |||||
|
Clinical activity and safety of the EGFR |
Jong-Seok Lee, Keunchil Park, |
Date: Saturday 19 December Time: 16.30–17.30 Location: Hall 332 Abstract: 425PD Poster Discussion Session |
|||
|
Phase II study of BI1482694 in patients |
Pasi A. Jänne, Jeewoong Son, |
Date: Sunday 20 December Time: 13.30–14.15 Location: Exhibition and Poster Area Abstract: 476TiP Poster Display Session |
|||
| Afatinib*** | |||||
|
Second-line afatinib vs methotrexate |
Makoto Tahara, Ezra E. W. |
Date: Friday 18 December Time: 14.30–14.40 Location: Hall 332 Abstract: 3140 Proffered Paper Session Abstract available at time of presentation |
|||
|
Afatinib (A) vs gefitinib (G) as first-line |
Keunchil Park, Eng-Huat Tan, Li |
Date: Sunday 20 December Time: 16.30–16.45 Location: Hall 406 Abstract: LBA2 Proffered Paper Session Abstract available at time of presentation |
|||
|
Phase III trial of afatinib vs erlotinib in |
Keunchil Park, Wei Li, Caicun |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 443P Poster Display Session |
|||
|
Afatinib (A) versus chemotherapy (CT) |
Yi-Long Wu, Lecia V Sequist, |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 446P Poster Display Session |
|||
|
Overall survival (OS) with afatinib (A) vs |
Yi-Long Wu, Lecia V Sequist , |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 445P Poster Display Session |
|||
|
Phase IV study of afatinib as second-line |
Sumitra Thongprasert, Aurelia |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 477TiP Poster Display Session |
|||
|
Phase III study of afatinib vs methotrexate |
Ping Zhang Tang, Myung-Ju Ahn,
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 340TiP Poster Display Session |
|||
|
Phase III study of afatinib vs placebo as |
Chao Su Hu, Anthony Chan, Li |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 339TiP Poster Display Session |
|||
| Nintedanib**** | |||||
|
Efficacy of nintedanib/docetaxel in East |
Yi-Long Wu, Ying Cheng, Bong-Seog |
Date: Sunday 20 December Time: 13.50-14.15 Location: Exhibition and poster area Abstract: 438P Poster Display Session |
|||
| BI 836845***** | |||||
|
Phase Ib trial of afatinib and BI 836845 |
Daniel Shao Weng Tan, Chia-Chi |
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 479TiP Poster Display Session |
|||
*BI 1482694 is an investigational, novel, oral, 3rd-generation, EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with EGFR mutations including the resistance mutation T790M.
**Boehringer Ingelheim has an exclusive license and collaboration agreement with Hanmi Pharmaceutical Co. Ltd for the development and global commercialisation rights (except South Korea, China and Hong Kong) of BI 1482694 (HM61713).
***Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF ® and in the US under the brand name GILOTRIF ® for use in patients with distinct types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.
****Nintedanib is approved in the EU under the brand name VARGATEF ® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications.
*****BI 836845, is an investigational, IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 and neutralises growth-promoting signaling.
#
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For notes to editors please visit:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151218005186/en/
Contact information
Boehringer Ingelheim
Corporate Communications
Media
+ PR
Dr. Reinhard Malin
Phone: +49 6132 – 77 90815
Fax:
+49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
or
Further
Media Channels
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo